+++
title = 'Concord Biotech Limited: Q3 & 9M FY25 Earnings Call'
date = 2025-02-21
readTime = true
tags = ["Concord Biotech Limited", "Earnings Call", "February-2025"]
showTags = true

+++



## Earnings Call Transcript Analysis Report
## Financial Performance

*   **Revenue:** Q3 FY25 revenue stood at INR 244 crores compared to INR 240 crores in Q3 FY24, a 1% increase. 9 months FY25 revenue increased by 10% year-on-year to INR 770 crores (9 months FY24: INR 698 crores).
*   **EBITDA:** Q3 FY25 EBITDA stood at INR 98 crores with margins at 40.1%. EBITDA for 9 months FY25 stood at INR 315 crores, representing a growth of 6% year-on-year.
*   **Profit After Tax (PAT):** Q3 FY25 PAT stood at INR 76 crores with margins at 31.1%. PAT for 9 months FY25 stood at INR 231 crores as compared to INR 213 crores in the same period last year, a growth of 9% Y-o-Y.
*   **API Revenue:** Q3 FY25 API revenues stood at INR 176 crores against INR 172 crores in Q3 last year, a growth of 3% year-on-year (9.6% including interunit sales). API revenue in the 9 months of this year stood at INR 577 crores against INR 562 crores during the same period last year.
*   **Formulation Revenue:** Q3 FY25 Formulation segment stood at INR 67 crores. For 9 months FY25, revenues from the Formulation segment stood at INR 192 crores, up by 42% on a year-on-year basis.
*   **Guidance:** Long-term guidance of achieving a 25% CAGR growth over the next 5 years is maintained.
*   **Margins:** Long-term sustainable EBITDA margin guidance is in the range of 40% to 43%.

## Strategic Initiatives & Business Updates

*   **Product Expansion:** Aim to introduce 8 to 10 additional products over the next 3 years, with a strong focus on oncology and anti-infectives.
*   **CDMO Business:** Seeing a growing number of inquiries and multiple RFQs being submitted. Now seen as a medium-term growth driver.
*   **Investment in Palvella Therapeutics Inc.:** Strategic investment of \$1 million in compulsory convertible notes to pave the way for a strategic partnership focused on the manufacturing and commercialization of QTORIN.
*   **Investment in CleanMax Private Limited:** Acquiring a 26% equity stake in CleanMax to power Dholka plant with renewable energy.
*   **Injectable Plant:** Scheduled to begin commercial production in the current quarter.
*   **Sustainability:** Honored with the Sustainability Reporting Award from the Institute of Chartered Accountants of India.

## Market & Competitive Landscape

*   **Formulation Business:** Gaining strong acceptance among customers across various regions.
*   **Strategic Focus:** Target domestic and emerging markets, leveraging expertise and market reach with an opportunistic approach for the regulated markets.
*   **Global Presence:** Goal to establish a strong global presence and achieve market leadership, targeting a sizeable global market share within the next 5 years.

## Risk Factors & Challenges

*   **Customer Procurement Patterns:** "Customer procurement patterns may lead to lumpiness, with some quarters experiencing higher procurement than others."
*   **Calendar Year Closure:** Formulation segment revenues were impacted due to calendar year closure for many global clients.

## Forward-Looking Statements

*   **Growth Outlook:** Positive outlook, in line with long-term guidance of achieving a 25% CAGR growth over the next 5 years.
*   **Formulation Business Growth:** Anticipate substantial growth in both product offerings and customer acquisition in the Formulation business.
*   **CDMO Growth:** CDMO is now seen as a medium-term growth driver.
*   **Injectable Plant Revenue:** Revenue generation from the injectable plant is expected to build up over the next financial year.

## Q&A Insights

*   **Revenue Growth:** Analyst questioned if the current year growth guidance would be revised downward given the trailing 12-month revenues.
*   **CDMO:** Analyst questioned the CDMO contracts.
*   **Capacity Utilization:** Questions regarding the capacity utilization of all facilities.

## Management Tone & Sentiment

*   **Stable Performance:** Pleased to report stable performance for Q3 FY '25.
*   **Positive Outlook:** Outlook remains positive, in line with long-term guidance.
*   **Emphasis on Annual Assessment:** "I would still emphasize to assess our financial results on an annualized basis rather than a quarterly one."



{{< rawhtml >}}

<div class="button-container">    
    <a href="https://www.bseindia.com/xml-data/corpfiling/AttachHis/2331ef6f-b29f-45a9-8504-a240ea1b4f36.pdf" target="_blank" class="report-button">
      <i class="fas fa-file-pdf"></i> Download Transcript
    </a>
</div>
    
{{< /rawhtml >}}
